Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials

Serebruany, Victor L., Malinin, Alex I., Eisert, Roswith M., Sane, David C.·2004·American Journal of Hematology

Abstract

Antiplatelet therapy has been the focus of extensive clinical investigations over the last two decades. A variety of agents and regimens have been advanced for the prevention and treatment of vascular disease. Despite the proven life‐saving clinical benefits of inhibiting platelets, this therapy is associated with an increased risk of bleeding. The objective of this study was to determine the risk of hemorrhage in the major classes of antiplatelet agents. Data from clinical trials published 1988–2002 in English were retrieved from MEDLINE, OVID, and CARDIOSOURCE. Only those studies in which patients had clinical follow‐up for at least 1 month and in which a full description of hemorrhagic complications was reported were included. Information on sample size, study design, duration, agent, patient characteristics, and bleeding severity was independently and blindly reviewed. Data from 51 clinical trials with a total of 338,191 patients were analyzed. The antiplatelet agents were divided into 6 groups: aspirin (ASA) < 100 mg; ASA ≥ 100 mg; dipyridamole, thienopyridines; intravenous and oral GP IIb/IIIa inhibitors. The variance estimate and confidence intervals were calculated for each treatment assignment. Low‐dose aspirin and dipyridamole therapy were associated with the lowest risk of bleeding (3.6% and 6.7%, respectively). The highest rate of bleeding complications (44.6%) was associated with the GP IIa/IIIb inhibitors. Despite substantial differences in the reporting patterns of bleeding complications, low‐dose ASA and dipyridamole therapy were associated with the lowest risk. Surprisingly, doses of ASA ≥ 100 mg caused a relatively high hemorrhagic event rate, which was comparable to that of ADP‐receptor blockers. These findings should be considered when using combination antiplatelet and/or anticoagulant therapy with conventional doses of ASA. Am. J. Hematol. 75:40–47, 2004. © 2003 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.10451

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Serebruany, V. L., Malinin, A. I., Eisert, R. M., & Sane, D. C.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2003-12-19
Volume
75
Issue
1
Pages
40-47
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W1993323415
Cited by
198
References
4
FWCI
6.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials. https://app.cochat.ai/papers/10.1002/ajh.10451
The paper
Serebruany, V. L., Malinin, A. I., Eisert, R. M., & Sane, D. C. (2004). Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials. American Journal of Hematology. https://doi.org/10.1002/ajh.10451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.